Table 3.
Recurrence sites by treatment group
| Sites of recurrence | ASCT | MT | P-value |
|---|---|---|---|
| Intention to treat | % of 149 patients | % of 146 patients | |
| All recurrences | 54 | 63 | 0.156 |
| Primary tumour | 26 | 31 | 0.365 |
| Metastases | 50 | 57 | 0.727 |
| Osteomedullary | 34 | 34 | 0.847 |
| Bone marrow | 23 | 21 | 0.607 |
| CNS* | 10 | 13 | 0.325 |
| Lymph nodes | 5 | 6 | 1.000 |
| Liver | 6 | <1 | 0.008 |
| Other | <1 | <1 | 1.000 |
| As treated | % of 110 patients | % of 102 patients | |
| All recurrences | 48 | 72 | 0.001 |
| Primary tumour | 24 | 39 | 0.018 |
| Metastases | 38 | 53 | 0.038 |
| Osteomedullary | 29 | 36 | 0.820 |
| Bone marrow | 18 | 21 | 1.000 |
| CNS* | 14 | 12 | 0.365 |
| Lymph nodes | 4 | 7 | 0.542 |
| Liver | 6 | 2 | 0.132 |
| Other | <1 | <1 | 1.000 |
| Treated as randomised | % of 75 patients | % of 70 patients | |
| All recurrences | 47 | 73 | 0.002 |
| Primary tumour | 21 | 39 | 0.029 |
| Metastases | 40 | 56 | 0.068 |
| Osteomedullary | 28 | 40 | 0.540 |
| Bone marrow | 16 | 20 | 0.460 |
| CNS* | 11 | 13 | 0.473 |
| Lymph nodes | 4 | 10 | 0.283 |
| Liver | 7 | 0 | 0.013 |
| Other | 1 | 1 | 0.684 |